Hemophilia Treatment Market Size & Share Forecast 2021-2027

report image

Hemophilia Treatment Market to 2027 - Global Analysis and Forecasts by Product (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic Agents); Disease (Hemophilia A, Hemophilia B, Hemophilia C); Treatment Type (On-demand, Prophylaxis); Therapy (Replacement Therapy, ITI Therapy, Gene Therapy, Antibody Therapy); End User (Hospitals, Clinics, Ambulatory Surgical Centres, Others), and Geography

Publication Month: Feb 2020 | Report Code: TIPRE00008241 | No. of Pages: 225 | Category: Pharmaceuticals | Status: Published

The hemophilia treatment market was valued at US$ 12,797.36 million in 2019 and it is projected to reach US$ 20,507.92 million in 2027; it is expected to grow at a CAGR of 6.1% from 2020 to 2027.

Hemophilia is a hereditary genetic blood disorder that affects the capacity of the blood to clot due to the lack of a particular protein needed for blood clotting. The hemophilia is graded as Hemophilia A, Hemophilia B, and C. Many recombinant drugs, such as an antihemophilic factor or Factor VII, are injectable. Injectables are used before surgery to control and prevent bleeding episodes since the onset of action is rapid in comparison with other forms. The growth of the global hemophilia treatment market is attributed to the increasing prevalence of hemophilia and rise in favourable government initiatives. However, high cost related with hemophilia treatment is the major factor hindering the market growth.

The global hemophilia treatment market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Lucrative Regions for Global Hemophilia Treatment Market



Lucrative Regions for Global Hemophilia Treatment Market

Get more information on this report :

Market Insights

Increasing Prevalence of Hemophilia to Drive Global Hemophilia Treatment Market Growth

Hemophilia is a hereditary bleeding disorder that stops the blood from clotting normally. The primary symptom is uncontrolled, often spontaneous bleeding in different areas of the body. According to data from the National Hemophilia Foundation in 2020, Hemophilia A happens in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B.  The number of people with hemophilia in the US is anticipated to be about 20,000 individuals since 1994. Moreover, the incidence of hemophilia is not known across the world; however, it is likely to be above 400,000 people. Almost 75% of people with hemophilia worldwide are either undiagnosed or receive disparate treatment.

In Italy, according to the data of the National Center for Biotechnology Information (NCBI) in 2017, the number of registered people with bleeding disorders increased from about 7,000 in 2000 to ~8,500 in 2011, and more than 11,000 in 2015. The trend is due to an upsurge in the number of patients who are recorded, mainly in those with vWD type 1, mild hemophilia, or other factor deficiencies.

The prevalence of the disease in the Asian countries is also increasing at an alarming rate. For instance, as per the report of Haemophilia Foundation Australia, 2020, more than 2,800 people were diagnosed with varying degrees of severity in hemophilia in the country.

Thus, increasing prevalence of hemophilia, high cases of under-diagnosed hemophilia cases, and improving healthcare infrastructure will eventually drive the growth of the market for hemophilia treatment in the forecast period.

Product -Based Insights

In terms of product, the global hemophilia treatment market is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, and antifibrinolytic agents. In 2019, the plasma-derived coagulation factor concentrates segment held largest share of the market. However, recombinant coagulation factor concentrates segment is estimated to register the highest CAGR during the forecast period.

Global Hemophilia Treatment Market, by Product – 2019 and 2027



Global Hemophilia Treatment Market, by Product – 2019 and 2027

Get more information on this report :


Disease-Based Insights

Based on disease, the global hemophilia treatment market is segmented into hemophilia A, hemophilia B, and hemophilia C. The hemophilia A segment held the largest market share in 2019. However, hemophilia B segment is estimated to grow at the fastest rate during the forecast period.

Treatment Type-Based Insights

Based on treatment type, the global hemophilia treatment market is segmented into prophylaxis and on-demand. The prophylaxis segment held the largest market share in 2019. However, the on-demand segment is estimated to grow at the fastest rate during the forecast period.

Therapy -Based Insights

Based on therapy, the global hemophilia treatment market is segmented into replacement therapy, ITI therapy, and gene therapy. The replacement therapy segment held the largest market share in 2019. Also, the same segment is estimated to register the highest CAGR during the forecast period.

End User-Based Insights

In terms of end user, the global hemophilia treatment market is segmented into hospitals & clinics, hemophilia treatment centers, and ambulatory surgical centers. The hospitals and clinics segment held the largest share of the market in 2019, and the same segment is estimated to grow at the fastest rate during the forecast period.

Strategic Insights

Report Coverage - Hemophilia Treatment Market
Report CoverageDetails
Market Size Value inUS$ 12,797.36 Million in 2019
Market Size Value byUS$ 20,507.92 Million by 2027
Growth rateCAGR of 6.1% from 2020-2027
Forecast Period2020-2027
Base Year2020
No. of Pages225
No. of Tables169
No. of Charts & Figures79
Historical data availableYes
Segments coveredProduct ; Disease ; Treatment Type ; Therapy ; End User , and Geography
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

The global hemophilia treatment market players are adopting the product launch and expansion strategies to cater to changing customer demands worldwide, which also allows them to maintain their brand name globally.

Global Hemophilia Treatment Market – by Product

  • Plasma Derived Coagulation Factor Concentrates
    • Factor VIII
    • Factor IX
    • Factor XII
    • Activated Prothrombin Complex Concentrate
    • Von Willebrand Factor
  • Recombinant Coagulation Factor Concentrates
    • Factor VIII
    • Factor IX
  • Antifibrinolytic Agents
  • Desmopressin

Global Hemophilia Treatment Market – by Disease

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C

Global Hemophilia Treatment Market – by Treatment Type

  • Prophylaxis
  • On-demand

Global Hemophilia Treatment Market – by Therapy

  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy   

Global Hemophilia Treatment Market – by End- User

  • Hospitals & Clinics
  • Hemophilia Treatment Centers
  • Ambulatory Surgical Centres

Global Hemophilia Treatment Market – by Geography

  • North America

    • US
    • Canada
    • Mexico
  • Europe

    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)

    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East & Africa (MEA)

    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South America and Central America (SCAM)

    • Brazil
    • Argentina
    • Rest of SCAM

Company Profiles

  • Bayer AG
  • Sanofi
  • F. Hoffmann-la Roche Ltd.
  • Kedrion S.P.A.
  • CSL Limited
  • Biotest AG
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Octapharma AG
  • Baxter International Inc.

Frequently Asked Questions

Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy. The treatment of disease includes replacement therapy and gene therapy. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII for hemophilia A, or IX for hemophilia B.
Rise in increasing prevalence of hemophilia, rise in favourable government initiatives to drive the growth of the global hemophilia treatment market during the forecast period. Moreover, growth of healthcare infrastructure among the untapped nations and increased initiatives taken up by governments are expected to fuel the growth of this market during the forecast period.
There are various type of therapy used in the treatment of hemophila disorder, such as replacement therapy, ITI therapy and gene therapy.

The List of Companies - Hemophilia Treatment Market

  1. Bayer AG
  2. Sanofi
  3. F. Hoffmann-la Roche Ltd.
  4. Kedrion S.P.A.
  5. CSL Limited
  6. Biotest AG
  7. Pfizer Inc.
  8. Novo Nordisk A/S
  9. Octapharma AG
  10. Baxter International Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the hemophilia treatment.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global hemophilia treatment, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
TIPRE00008241
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




tip-analyst

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $3000
  • $4550 $3640
  • $6550 $5240
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount